HLA-A*0201-restricted TERT(572Y)/TERT(572) peptides vaccine Vx-001

{
  "id": "MLC-T-ONC-014129",
  "term": "HLA-A*0201-restricted TERT(572Y)/TERT(572) peptides vaccine Vx-001",
  "field": "Oncology and biomedicine",
  "definition": "A peptide-based cancer vaccine consisting of two human leukocyte antigen (HLA)-A*0201 restricted 9-mer epitopes derived from the human telomerase reverse transcriptase (hTERT), TERT 572Y (YLFFYRKSV; TYR-Vx001) and TERT 572 (RLFFYRKSV; ARG-Vx001), with potential immunostimulating and antineoplastic activities. Subcutaneous injection of TERT(572Y) peptide followed by subcutaneous administration of the TERT(572) peptide may elicit a specific and possibly optimal cytotoxic T cell (CTL) response against hTERT-expressing tumor cells. hTERT, the catalytic subunit of human telomerase, is a human leukocyte antigen-A*0201-restricted cryptic epitope of telomerase. TERT is expressed in the majority of human cancer cells, is not expressed or is expressed at very low levels in normal cells and plays a key role in tumorigenesis. TERT572Y is the optimized variant of the native cryptic peptide TERT572 in which tyrosine has been substituted for an arginine at position 1; TERT572Y shows increased HLA-A*0201 binding affinity compared to TERT572.",
  "synonyms": [
    "HLA-A*0201 restricted telomerase-specific vaccine Vx-001"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/hla-a-0201-restricted-tert-572y-tert-572-peptides-vaccine-vx-001/"
}